COVID‐19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta‐analysis. (11th December 2022)

• Record Type: Journal Article
• Authors: Lee, Min Ho; Li, Han Jacob; Wasuwanich, Paul; Kim, Sung Eun; Kim, Jong Yeob; Jeong, Gwang Hun; Park, Seoyeon; Yang, Jae Won; Kim, Min Seo; Yon, Dong Keon; Lee, Seung Won; Koyanagi, Ai; Jacob, Louis; Kim, Eun‐Young; Cheon, Jae Hee; Shin, Jae Il; Smith, Lee
• Is Part Of: Reviews in medical virology. Volume 33:Number 2(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-11
• Subjects: COVID‐19 -- Crohn's disease -- inflammatory bowel disease -- meta‐analysis -- ulcerative colitis; Medical virology -- Periodicals; Review Literature -- Periodicals; Virus Diseases -- Periodicals; Viruses -- Periodicals; 616.0194
• DOI: 10.1002/rmv.2414
• Languages: English
• ISSNs: 1052-9276

Abstract

Abstract: The susceptibility, risk factors, and prognosis of COVID‐19 in patients with inflammatory bowel disease (IBD) remain unknown. Thus, our study aims to assess the prevalence and clinical outcomes of COVID‐19 in IBD. We searched PubMed, EMBASE, and medRxiv from 2019 to 1 June 2022 for cohort and case‐control studies comparing the prevalence and clinical outcomes of COVID‐19 in patients with IBD and in the general population. We also compared the outcomes of patients receiving and not receiving 5‐aminosalicylates (ASA), tumour necrosis factor antagonists, biologics, systemic corticosteroids, or immunomodulators for IBD. Thirty five studies were eligible for our analysis. Pooled odds ratio of COVID‐19‐related hospitalisation, intensive care unit (ICU) admission, or death in IBD compared to in non‐IBD were 0.58 (95% confidence interval (CI) = 0.28–1.18), 1.09 (95% CI = 0.27–4.47), and 0.67 (95% CI = 0.32–1.42), respectively. Inflammatory bowel disease was not associated with increased hospitalisation, ICU admission, or death. Susceptibility to COVID‐19 did not increase with any drugs for IBD. Hospitalisation, ICU admission, and death were more likely with 5‐ASA and corticosteroid use. COVID‐19‐related hospitalisation (Odds Ratio (OR): 0.53; 95% CI = 0.38–0.74) and death (OR: 0.13; 95% CI = 0.13–0.70) were less likely with Crohn's disease than ulcerative colitis (UC). In conclusion, IBD does not increase the mortality and morbidity of COVID‐19. However, physicians should be aware that additional monitoring is needed in UC patients or in patients taking 5‐ASA or systemic corticosteroids.